Rapport Therapeutics, Inc. beat EPS estimates 67% of the time across 9 reported quarters (6 beats, 3 misses), averaging -12.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.93 | $-1.19 | -28.0% | Miss | |
| Q1 FY26 | $-0.56 | $-0.42 | +25.0% | Beat | |
| Q4 FY25 | $-0.65 | $-0.72 | -10.8% | Miss | |
| Q3 FY25 | $-0.77 | $-0.71 | +7.8% | Beat | |
| Q2 FY25 | $-0.87 | $-0.75 | +13.8% | Beat | |
| Q1 FY25 | $-0.77 | $-0.68 | +11.7% | Beat | |
| Q4 FY24 | $-0.62 | $-0.57 | +8.1% | Beat | |
| Q3 FY24 | $-0.57 | $-0.50 | +12.3% | Beat | |
| Q2 FY24 | $-0.68 | $-1.70 | -150.0% | Miss |
Back to RAPP overview · RAPP holders · RAPP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.